- |||||||||| Victoza (liraglutide) / Novo Nordisk
Preclinical, Review, Journal: Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes. (Pubmed Central) - Jun 13, 2024
Furthermore, the present study recommends that more reasonable usage methods of streptozotocin, including dosage and injection methods, as well as other types of osteoporosis models, be attempted in future studies. Based on the results, this finding may help to improve the priority of Lrg in the treatment of diabetes patients with osteoporosis.
- |||||||||| aroxybutynin/atomoxetine (AD109) / Apnimed
Enrollment open: APC-APN-201: Study That Tests AD109 in Patients Taking GLP-1 Drugs (clinicaltrials.gov) - Jun 6, 2024
P2, N=40, Recruiting,
Among the GLP-1 agonist medications, liraglutide has been found to have an association with pancreatitis. Not yet recruiting --> Recruiting
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Journal: Comparative Analysis of the Anti-Inflammatory Effects of Liraglutide and Dulaglutide. (Pubmed Central) - Jun 2, 2024
The difference between the two resided in the extended intervention duration required to observe the effect of dulaglutide, and liraglutide demonstrated a superior dose-dependent manner. We provide a potential strategy to understand the dynamics of drug action and possible timing administration.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Journal: High glucose promotes atherosclerosis by regulating miRNA let7d-5p level. (Pubmed Central) - Jun 1, 2024
The recommendations should also consider the patient's preferences and the available resources and expertise. High glucose stimulated the proliferation and migration of VSMCs by regulating the let7d-5p/HMGA2/GSK3?/?-catenin pathway, and liraglutide may slow atherosclerosis by increasing the levels of miR let7d-5p.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Impact of GLP1R and its agonists in pulmonary circulation (PS-6; Poster board no. 11) - May 31, 2024 - Abstract #ERS2024ERS_2076;
Liraglutide shows an antiproliferative effect in hPASMCs and hPAECs. In addition, it induces vasodilation independent of its receptor, suggesting a potential therapeutic benefit in the treatment of PAH.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Reimbursement, US reimbursement, Journal, Medicare: Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable. (Pubmed Central) - May 31, 2024
Glucagon-like peptide-1 receptor agonists are effective for treating obesity, but the high cost of these medications endangers the financial viability of our health care system. To ensure that these drugs are available to Medicare beneficiaries, pharmaceutical manufacturers must lower their prices.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Preclinical, Journal: Prediction of subcutaneous drug absorption - Development of novel simulated interstitial fluid media for predictive subcutaneous in vitro assays. (Pubmed Central) - May 30, 2024
The novel SISFs were used in initial in vitro diffusion studies with a commercial injectable preparation of liraglutide. Although the in vitro model used for this purpose still requires significant refinement, these two new media will undoubtedly contribute to a better understanding of the in vivo performance of subcutaneous injectables in different species and will help to reduce the number of unnecessary in vivo experiments in preclinical species by implementation in predictive in vitro models.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Journal: Can Unmet Needs Be Addressed by Adjunctive Therapies? Findings from a Patient Perspectives Survey in Adults with Type 1 Diabetes. (Pubmed Central) - May 27, 2024
A quantitative online survey (n?=?133) assessed (1) self-reported demographic and management data, (2) management priorities, satisfaction, and willingness to use adjunctive therapies and (3) conducted a risk-benefit analysis using three masked drug profiles (1.8 mg vs 0.6 mg liraglutide vs placebo)...Individuals with T1D self-report many unmet needs. While not currently approved in T1D, GLP-1RA properties align with many management priorities reported by individuals with T1D.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Byetta (exenatide) / AstraZeneca
Preclinical, Journal: Lymphatic uptake of the lipidated and non-lipidated GLP-1 agonists liraglutide and exenatide is similar in rats. (Pubmed Central) - May 25, 2024
The low lymphatic uptake may be due to the nature of the conjugated lipid (a single-chain C16 palmitic acid in liraglutide) but suggests that other peptides with similar lipid conjugations may also have relatively modest lymphatic uptake. If delivery to the lymph is desired, conjugation to more lipophilic moieties with higher albumin and/or lipoprotein binding efficiencies, such as diacylglycerols, may be appropriate.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Review, Journal: Lipotoxicity: The missing link between diabetes and periodontitis? (Pubmed Central) - May 23, 2024
By elucidating potential therapeutic strategies targeting lipotoxicity and describing their associated mechanisms and clinical outcomes, including metformin, statins, liraglutide, adiponectin, and omega-3 PUFA, this review seeks to provide a more comprehensive and effective treatment framework against diabetes-associated periodontitis. Furthermore, the challenges and future research directions are proposed, aiming to contribute to a more profound understanding of the impact of lipotoxicity on periodontitis.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Glucose Tolerance and Glucagon-Like Peptide-1 Sensitivity in Offspring Exposed to Prenatal Hyperglycemia (Poster Hall (West A4-B2); 1207) - May 20, 2024 - Abstract #ADA2024ADA_3069;
Control and PHGE were subjected to OGTT at 50 days of age and intraperitoneal glucose tolerance test (IPGTT) at 60 days of age, and were divided into two subgroups, one receiving 1.8 mg/60 kg (0.03 mg/kg) i.p. of liraglutide (Lira) 30 minutes before the loading test and the other receiving the same volume of phosphate buffer solution (PBS)... Impaired glucose tolerance in PHGE was shown to be partly due to decreased insulin secretion caused by reduced GLP-1 sensitivity.
- |||||||||| Potential for New Oral Insulin Sensitizers in Combination with GLP-1 Agonists (Poster Hall (West A4-B2); 892) - May 20, 2024 - Abstract #ADA2024ADA_2897;
MSDC-0602K (azemiglitazone) is a second-generation insulin sensitizer that was designed based on the knowledge of the activity of active metabolites of the first-generation insulin sensitizer pioglitazone...Here we have looked specifically at the 23 subjects with NASH (MASH) and type 2 diabetes who had been enrolled in the trial while on a stable dose of a GLP1 agonist (11 liraglutide, 8 dulaglutide, and 4 exenatide)...Some subjects who had been on a GLP1 continued to lose weight while others did not. Given the major effects of his pharmacology to improve insulin sensitivity Iin skeletal muscle and based on some existing precedent with high dose pioglitazone, maintenance of lean mass could be a component of the overall pharmacology achieved with oral metabolic modulators.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Role of Glucagon-Like-Peptide-1 Agonists as an Adjunctive Treatment in Adults with Type 1 Diabetes Mellitus and Overweight/Obesity, Retrospective Cohort, Saudi Arabia 2023 (Poster Hall (West A4-B2); 810) - May 20, 2024 - Abstract #ADA2024ADA_2843;
32 patients on GLP-1 agonists were recruited, with a mean age of 30 years, 87% were on Semaglutide (0.5mg or 1mg), while the rest were on Liraglutide (1.2mg-3mg), Estimated Hga1c reduction was 0.84% after 8 months from baseline, p-value <0.001... GLP-1 agonist as adjunctive therapy to insulin shows a significant Improvement in Glycemic control, weight reduction, and insulin requirement in patients with Type-1 diabetes.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Effectiveness of a Hybrid Weight Loss Program for Obesity and Prediabetes Using GLP-1 Medications (Poster Hall (West A4-B2); 806) - May 20, 2024 - Abstract #ADA2024ADA_2839;
Total cholesterol levels decreased by -16.08 mg/dL (-8.3%) (p = 0.005). The hybrid program resulted in a 16.2% more reduction in weight compared to STEP-2 trial results which involved in-clinic only behavioral change advice.The use of GLP-1 medications delivered in a hybrid mode, demonstrated significant positive changes across all parameters, suggesting the potential of this approach for managing obesity and pre-diabetes using GLPs for more effective changes.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Byetta (exenatide) / AstraZeneca, Adlyxin (lixisenatide) / Sanofi
TRIM (Poster Hall (West A4-B2); 801) - May 20, 2024 - Abstract #ADA2024ADA_2833;
GLP1RAs reduce weight-related outcomes in adolescents with Semaglutide being the most efficacious. RCTs with direct comparisons, pragmatic study design, longer follow-up (to generate or verify safety signals), and adiposity-related outcomes are needed to further guide the usage and choice of GLP1RAs.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Post Hoc Analysis of Phase III Study of Liraglutide Biosimilar with Reference Biologic in Obese Type 2 Diabetes Mellitus Indians (Poster Hall (West A4-B2); 800) - May 20, 2024 - Abstract #ADA2024ADA_2832;
RCTs with direct comparisons, pragmatic study design, longer follow-up (to generate or verify safety signals), and adiposity-related outcomes are needed to further guide the usage and choice of GLP1RAs. Biosimilar of Liraglutide demonstrated comparable glycemic control with respect to the reference biologic in terms of reduction in HbA1c, FPG and PPBG from baseline to Week 24 in obese T2DM patients.
- |||||||||| ecnoglutide SC (XW003) / Sciwind Biosci
Biased GLP-1 Analog Ecnoglutide (XW003) Has Improved Efficacy Relative to Unbiased Peptides (Poster Hall (West A4-B2); 793) - May 20, 2024 - Abstract #ADA2024ADA_2824;
Funding By Sciwind Biosciences Introduction & Objective: Ecnoglutide (XW003) is a cAMP-biased GLP-1 analog being developed for the treatment of type 2 diabetes mellitus (T2DM) and obesity. Bias for the cAMP pathway results in sustained signaling that correlates with increased clinical efficacy compared to unbiased GLP-1 analogs.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Liraglutide Rapid Effects on Glucose and Adipose Tissue during and after CABG (Poster Hall (West A4-B2); 449) - May 20, 2024 - Abstract #ADA2024ADA_2743;
P4
Off-label use of tirzepatide increased sharply among adults without T2D during its first 13 months on the market, even though it was not approved for the treatment of obesity until November 2023. This RCT shows for the first time that short-term pre-CABG liraglutide induces significant beneficial cardio-metabolic effects, such as better intra- and post-operative glucose control, EAT changes and post-operative weight loss.
- |||||||||| petrelintide (ZP8396) / Zealand Pharma
Petrelintide (ZP8396) Significantly Reduces Fat Mass while Preserving Lean Mass in DIO Rats (Poster Hall (West A4-B2); 1662) - May 20, 2024 - Abstract #ADA2024ADA_2609;
Based on these findings, petrelintide could hold the potential to reduce the loss of lean body mass associated with weight loss in humans. Petrelintide is currently being explored in a multiple ascending dose (MAD) study to assess the potential for the management of obesity.
- |||||||||| petrelintide (ZP8396) / Zealand Pharma
Petrelintide (ZP8396) Selectively Reduces Intake of High-Fat Diet in DIO Rats (Poster Hall (West A4-B2); 1661) - May 20, 2024 - Abstract #ADA2024ADA_2608;
Based on these findings petrelintide might hold the potential to address overconsumption of highly palatable food in humans. Petrelintide is currently being explored in a multiple ascending dose (MAD) study to assess the potential for the management of obesity.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Leqvio (inclisiran) / Novartis
Nonhuman Primate Obesity Model for the Translation of Target-Based Precision Medicine (Poster Hall (West A4-B2); 1647) - May 20, 2024 - Abstract #ADA2024ADA_2594;
Petrelintide is currently being explored in a multiple ascending dose (MAD) study to assess the potential for the management of obesity. Furthermore, monkeys showed similar response as observed in humans after the administration of reference or test compounds, such as liraglutide, semaglutide, inclisiran, pioglitazone, empagliflozin etc. Significant reduction in food intake (-38.5
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Low CRP Alleles in HNF1A Are Associated with Increased Risk of Cardiovascular Disease (Poster Hall (West A4-B2); 1472) - May 20, 2024 - Abstract #ADA2024ADA_2554;
Our study has revealed an association between low CRP alleles in HNF1A and an elevated risk of CVD, possibly due to dyslipidemia or poor glycemic control. This suggests that for MODY3 patients, it may be more reasonable to prioritize anti-diabetic with cardiovascular protection such as GLP-1 receptor agonist, but not sulfonylureas.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
GLP-1 Agonist Therapy in Adolescents and Young Adults with Type 1 Diabetes (Poster Hall (West A4-B2); 1182) - May 20, 2024 - Abstract #ADA2024ADA_2517;
GLP-1 use among AYA with T1D was well-tolerated and associated with improved metabolic measures in a real-world setting. Randomized controlled trials assessing long-term clinical efficacy are warranted.
|
